LAB$1.18
$1.25
Chart
Performance
Key Stats
AI LAB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldStandard BioTools Inc. (LAB) presents a mixed investment profile. Fundamentally, the company is struggling with profitability and negative EPS, though it has significant assets and a market cap indicating investor interest. Technologically, the company is involved in promising areas like spatial biology and genomics. However, the current stock price action and negative performance trends, coupled with the lack of dividends, suggest a cautious approach. It may be suitable for investors with a high-risk tolerance looking for potential turnaround plays in the biotech sector, but diversification is crucial.
Thematic
Standard BioTools operates in the promising life sciences sector, focusing on proteomics and genomics, which have strong long-term thematic tailwinds driven by advancements in personalized medicine, diagnostics, and drug discovery. The company's technologies like SomaScan, CyTOF, and Hyperion are at the forefront of biological research.
Fundamental
Standard BioTools' fundamentals are currently weak. The company is unprofitable, with negative EPS and net margins. Revenue has been inconsistent, and while assets are substantial, liabilities are also significant. The lack of dividends and negative free cash flow indicate financial strain.
Technical
The stock's recent performance has been volatile, with significant price drops over the past year. While there have been some short-term positive movements, the overall trend appears downward, and key technical indicators suggest caution. The company has no dividend history.
| Factor | Score |
|---|---|
| Biotechnology & Life Sciences Innovation | 80 |
| Genomic and Proteomic Advancements | 75 |
| Spatial Biology | 70 |
| Market Adoption & Competition | 50 |
| Research & Development Focus | 65 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 10 |
| Growth | 50 |
| Balance Sheet Health | 60 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Analysis | 60 |
| Support & Resistance | 55 |
| Moving Averages | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Short-Term Performance
The stock has shown strong recent performance, with a 1-month return of 19.33% and a 5-day return of 4.41%.
Improving Cash Position
Cash and cash equivalents have significantly increased from $51.7 million in Q4 2023 to $166.7 million in Q4 2024, indicating improved liquidity.
Bearish Points (8)
Negative Earnings and Profitability
The company has consistently reported negative EPS (e.g., -0.32 TTM) and negative net income, indicating ongoing unprofitability.
Declining Revenue and Negative Net Margin
Revenue has fluctuated, with Q4 2024 revenue of $46.7M compared to $106.3M in Q4 2023. The net margin remains significantly negative (-72.9% in Q4 2024).
Calendar
August 2025
12
Next Earnings Date
H: $-0.04
A: $-0.04
L: $-0.04
H: 41.70M
A: 39.83M
L: 37.20M
Profile
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Seasonals
Price Target
1.93 USD
The 39 analysts offering 1 year price forecasts for LAB have a max estimate of 2.25 and a min estimate of 1.60.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Primary direct competitor in clinical diagnostic laboratory services, offering a broad range of routine and specialized testing.
Weight: 95
Leading supplier of scientific instruments, reagents, consumables, and software to laboratories worldwide; also has a significant diagnostics and clinical trials services segment.
Weight: 92
Diversified science and technology company with significant businesses in diagnostics, life sciences, and environmental & applied solutions, providing tools and services critical for labs.
Weight: 90
Major global player in diagnostics, medical devices, nutrition, and generic pharmaceuticals, supplying various testing platforms and reagents to clinical laboratories.